{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T05:30:07Z","timestamp":1774675807486,"version":"3.50.1"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006096","name":"Shiraz Transplant Research Center, Shiraz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.intimp.2020.106924","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T07:43:14Z","timestamp":1597995794000},"page":"106924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Immunotherapeutic approaches to curtail COVID-19"],"prefix":"10.1016","volume":"88","author":[{"given":"Hajar","family":"Owji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manica","family":"Negahdaripour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasim","family":"Hajighahramani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.106924_b0005","first-page":"1","article-title":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics","author":"Dhama","year":"2020","journal-title":"Hum. Vaccines & Immunotherapeutics"},{"issue":"2","key":"10.1016\/j.intimp.2020.106924_b0010","first-page":"81","article-title":"The battle against COVID-19: where do we stand now?","volume":"45","author":"Negahdaripour","year":"2020","journal-title":"Iranian J. Med. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0015","first-page":"231","article-title":"The rise and fall in therapeutic candidates for COVID-19","volume":"45","author":"Negahdaripour","year":"2020","journal-title":"Iranian J. Med. Sci."},{"key":"10.1016\/j.intimp.2020.106924_b0020","article-title":"Therapeutic approaches for COVID-19 based on the dynamics of interferon-mediated immune responses","author":"Shahabinezhad","year":"2020","journal-title":"Preprints"},{"issue":"7","key":"10.1016\/j.intimp.2020.106924_b0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41577-020-0346-x","article-title":"Dysregulation of type I interferon responses in COVID-19","volume":"20","author":"Acharya","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.106924_b0030","article-title":"Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells","author":"Muus","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.intimp.2020.106924_b0035","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3330","article-title":"DPP4 inhibition: Preventing SARS-CoV-2 infection and\/or progression of COVID-19?","author":"Strollo","year":"2020","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"10230","key":"10.1016\/j.intimp.2020.106924_b0040","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(20)30691-7","article-title":"Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","volume":"395","author":"Ritchie","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.intimp.2020.106924_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","author":"Rothan","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2020.106924_b0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"2","author":"Li","year":"2020","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.intimp.2020.106924_b0055","first-page":"1","article-title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection\u2014\u2014a review of immune changes in patients with viral pneumonia","author":"Lin","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0060","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/22221751.2020.1780953","article-title":"SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists","volume":"9","author":"Yuen","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.intimp.2020.106924_b0065","doi-asserted-by":"crossref","unstructured":"Y. Konno, et al., SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant. bioRxiv, 2020: 2020.05.11.088179.","DOI":"10.1101\/2020.05.11.088179"},{"key":"10.1016\/j.intimp.2020.106924_b0070","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2123","article-title":"Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection","author":"Keam","year":"2020","journal-title":"Rev. Med. Virol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106924_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.intimp.2020.106924_b0080","article-title":"COVID-19 and the immune system","volume":"69","author":"Paces","year":"2020","journal-title":"Physiol. Res."},{"key":"10.1016\/j.intimp.2020.106924_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104791","article-title":"Type 1 interferons as a potential treatment against COVID-19","volume":"178","author":"Sallard","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2020.106924_b0090","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is enriched in specific cell subsets across tissues","volume":"5","author":"Ziegler","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2020.106924_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106688","article-title":"Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial","volume":"85","author":"Dastan","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s13054-020-03048-5","article-title":"Interferon beta-1a for COVID-19: critical importance of the administration route","volume":"24","author":"Jalkanen","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.intimp.2020.106924_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106740","article-title":"Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis","volume":"86","author":"Yu","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106924_b0110","first-page":"155","article-title":"A world of changes: the inheritance of COVID-19","volume":"45","author":"Negahdaripour","year":"2020","journal-title":"Iranian J. Med. Sci."},{"issue":"21","key":"10.1016\/j.intimp.2020.106924_b0115","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2020.106924_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.vacun.2020.05.002","article-title":"A review on promising vaccine development progress for COVID-19 disease","author":"Belete","year":"2020","journal-title":"Vacunas"},{"key":"10.1016\/j.intimp.2020.106924_b0125","article-title":"Vaccines for COVID-19: The current state of play","author":"Koirala","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"issue":"17","key":"10.1016\/j.intimp.2020.106924_b0130","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0135","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.intimp.2020.106924_b0140","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ajem.2020.04.035","article-title":"Pharmacotherapy in COVID-19; A narrative review for emergency providers","volume":"38","author":"Mehta","year":"2020","journal-title":"Am. J. Emergency Med."},{"key":"10.1016\/j.intimp.2020.106924_b0145","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jmv.25733","article-title":"Clinical trial analysis of 2019-nCoV therapy registered in China","volume":"92","author":"Zhang","year":"2020","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40064-015-1490-9","article-title":"Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol","volume":"4","author":"Arabi","year":"2015","journal-title":"Springerplus"},{"issue":"2","key":"10.1016\/j.intimp.2020.106924_b0155","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jinf.2013.03.015","article-title":"Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests","volume":"67","author":"Chan","year":"2013","journal-title":"J. Infect."},{"key":"10.1016\/j.intimp.2020.106924_b0160","doi-asserted-by":"crossref","DOI":"10.1111\/vox.12926","article-title":"Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how","author":"Tiberghien","year":"2020","journal-title":"Vox Sang."},{"key":"10.1016\/j.intimp.2020.106924_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102790","article-title":"TreaTment for emerging viruses: Convalescent plasma and COVID-19","author":"Brown","year":"2020","journal-title":"Transfus. Apheres. Sci."},{"issue":"1718","key":"10.1016\/j.intimp.2020.106924_b0170","article-title":"Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives\u2013current situation and perspectives","volume":"150","author":"Marando","year":"2020","journal-title":"Swiss Med. Wkly"},{"key":"10.1016\/j.intimp.2020.106924_b0175","first-page":"1","article-title":"Convalescent plasma transfusion for the treatment of COVID-19: Systematic review","volume":"2020","author":"Rajendran","year":"2020","journal-title":"J. Med. Virol."},{"issue":"16","key":"10.1016\/j.intimp.2020.106924_b0180","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0185","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet. Infect. Dis"},{"key":"10.1016\/j.intimp.2020.106924_b0190","article-title":"A short review on antibody therapy for COVID-19","author":"Kumar","year":"2020","journal-title":"New Microbes New Infect."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0195","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","article-title":"Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients","volume":"1","author":"Zeng","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2020.106924_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104358","article-title":"Challenges of convalescent plasma therapy on COVID-19","volume":"127","author":"Zhao","year":"2020","journal-title":"J. Clin. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106924_b0205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2249.2003.02199.x","article-title":"Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin","volume":"133","author":"Brennan","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2020.106924_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in Covid-19: Possible mechanisms of action","author":"Rojas","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2020.106924_b0215","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000862","article-title":"SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity","volume":"8","author":"Wei","year":"2020","journal-title":"J. ImmunoTher. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0220","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaci.2020.04.043","article-title":"Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients\u2014a perspective","volume":"146","author":"Hammarstr\u00f6m","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2020.106924_b0225","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/bjh.16981","article-title":"Convalescent plasma for persisting Covid-19 following therapeutic lymphocyte depletion: a report of rapid recovery","volume":"190","author":"Clark","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2020.106924_b0230","article-title":"Convalescent (immune) plasma treatment in a myelodysplastic covid-19 patient with disseminated tuberculosis","volume":"102821","author":"\u00c7\u0131nar","year":"2020","journal-title":"Transfus. Apheres. Sci."},{"key":"10.1016\/j.intimp.2020.106924_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2020.06.046","article-title":"Rapid recovery of a SARS-CoV-2 infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma","author":"Mira","year":"2020","journal-title":"J. Allergy Clin. Immunology Practice"},{"issue":"14","key":"10.1016\/j.intimp.2020.106924_b0240","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e149","article-title":"Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea","volume":"35","author":"Ahn","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.intimp.2020.106924_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.htct.2020.04.003","article-title":"COVID-19 convalescent plasma transfusion","author":"Langhi","year":"2020","journal-title":"Hematol., Transfus. Cell Ther."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0250","first-page":"10","article-title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)","volume":"38","author":"Shanmugaraj","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.intimp.2020.106924_b0255","article-title":"Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2","author":"Park","year":"2020","journal-title":"bioRxiv"},{"issue":"7798","key":"10.1016\/j.intimp.2020.106924_b0260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.106924_b0265","first-page":"1","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"6483","key":"10.1016\/j.intimp.2020.106924_b0270","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.intimp.2020.106924_b0275","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s11427-017-9189-3","article-title":"Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses","volume":"60","author":"Zeng","year":"2017","journal-title":"Sci. China Life Sci."},{"issue":"2","key":"10.1016\/j.intimp.2020.106924_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0285","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.intimp.2020.106924_b0290","article-title":"Differential antibody recognition by novel SARS-CoV-2 and SARS-CoV spike protein receptor binding domains: mechanistic insights and implications for the design of diagnostics and therapeutics","author":"D'Annessa","year":"2020","journal-title":"bioRxiv"},{"issue":"11","key":"10.1016\/j.intimp.2020.106924_b0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050366","article-title":"Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing","volume":"7","author":"Elshabrawy","year":"2012","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.intimp.2020.106924_b0300","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm1080","article-title":"An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus","volume":"10","author":"Traggiai","year":"2004","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0305","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.virol.2006.09.029","article-title":"Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse\u00ae","volume":"361","author":"Coughlin","year":"2007","journal-title":"Virology"},{"issue":"28","key":"10.1016\/j.intimp.2020.106924_b0310","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.28.2000291","article-title":"Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2","volume":"25","author":"Zheng","year":"2020","journal-title":"Euro Surveill."},{"key":"10.1016\/j.intimp.2020.106924_b0315","first-page":"1","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","author":"Pinto","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.intimp.2020.106924_b0320","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0325","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12929-016-0234-7","article-title":"Surface vimentin is critical for the cell entry of SARS-CoV","volume":"23","author":"Yu","year":"2016","journal-title":"J. Biomed. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2020.106924_b0330","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/JVI.78.11.5642-5650.2004","article-title":"pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN","volume":"78","author":"Yang","year":"2004","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41426-018-0031-3","article-title":"Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism","volume":"7","author":"Seesuay","year":"2018","journal-title":"Emerg. Microbes Infect."},{"issue":"5626","key":"10.1016\/j.intimp.2020.106924_b0340","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.intimp.2020.106924_b0345","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.7150\/ijbs.45123","article-title":"Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2","volume":"16","author":"Zhou","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"20","key":"10.1016\/j.intimp.2020.106924_b0350","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2020.106924_b0355","article-title":"Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus","author":"Zhou","year":"2020","journal-title":"bioRxiv"},{"issue":"3","key":"10.1016\/j.intimp.2020.106924_b0360","first-page":"368","article-title":"TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor fedratinib","volume":"53","author":"Wu","year":"2020","journal-title":"J. Microbiol. Immunol."},{"issue":"13","key":"10.1016\/j.intimp.2020.106924_b0365","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0370","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respiratory Med."},{"key":"10.1016\/j.intimp.2020.106924_b0375","doi-asserted-by":"crossref","first-page":"13135","DOI":"10.1038\/srep13135","article-title":"Unique toll-like receptor 4 activation by NAMPT\/PBEF induces NF\u03baB signaling and inflammatory lung injury","volume":"5","author":"Camp","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0380","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1165\/rcmb.2017-0155OC","article-title":"Novel mechanism for nicotinamide phosphoribosyltransferase inhibition of TNF-\u03b1\u2013mediated apoptosis in human lung endothelial cells","volume":"59","author":"Oita","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"10223","key":"10.1016\/j.intimp.2020.106924_b0385","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.intimp.2020.106924_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.02.029","article-title":"Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection: Lymphopenia in severe COVID-19 infection","author":"Bermejo-Martin","year":"2020","journal-title":"J. Infect."},{"issue":"5","key":"10.1016\/j.intimp.2020.106924_b0395","article-title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors","volume":"12","author":"Bersanelli","year":"2020","journal-title":"Future Med."},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0400","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"Platt","year":"1998","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0405","first-page":"665","article-title":"Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus","volume":"11","author":"Woo","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0410","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123158","article-title":"Anti\u2013spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0415","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41232-016-0013-6","article-title":"Complement-targeted therapy: development of C5-and C5a-targeted inhibition","volume":"36","author":"Horiuchi","year":"2016","journal-title":"Inflamm. Regen."},{"issue":"3","key":"10.1016\/j.intimp.2020.106924_b0420","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0425","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/acs.jcim.5b00467","article-title":"Interpreting thermodynamic profiles of aminoadamantane compounds inhibiting the M2 proton channel of influenza A by free energy calculations","volume":"56","author":"Homeyer","year":"2016","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.intimp.2020.106924_b0430","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.coviro.2016.03.002","article-title":"Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine","volume":"17","author":"Cho","year":"2016","journal-title":"Curr. Opin. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0435","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","article-title":"Coronavirus envelope protein: current knowledge","volume":"16","author":"Schoeman","year":"2019","journal-title":"Virol. J."},{"key":"10.1016\/j.intimp.2020.106924_b0440","article-title":"Three options against SARS-CoV-2: pediatric sera, mithridatization, dewetting antibodies","author":"Tozzi","year":"2020","journal-title":"Preprint"},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0445","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/antib4010012","article-title":"Cell-free synthesis meets antibody production: a review","volume":"4","author":"Stech","year":"2015","journal-title":"Antibodies"},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0450","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/rmv.706","article-title":"Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential","volume":"22","author":"Coughlin","year":"2012","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.intimp.2020.106924_b0455","article-title":"Potent human neutralizing antibodies elicited by SARS-CoV-2 infection","author":"Ju","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.intimp.2020.106924_b0460","doi-asserted-by":"crossref","unstructured":"R. Kong, et al., COVID-19 Docking Server: An interactive server for docking small molecules, peptides and antibodies against potential targets of COVID-19. arXiv preprint arXiv:2003.00163, 2020.","DOI":"10.1093\/bioinformatics\/btaa645"},{"issue":"2","key":"10.1016\/j.intimp.2020.106924_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2020.106924_b0470","article-title":"SARS-CoV-2 and SARS-CoV spike-RBD structure and receptor binding comparison and potential implications on neutralizing antibody and vaccine development","author":"Xie","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.intimp.2020.106924_b0475","first-page":"1","article-title":"Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2020.106924_b0480","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1073\/pnas.0307140101","article-title":"Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association","volume":"101","author":"Sui","year":"2004","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.intimp.2020.106924_b0485","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1128\/JVI.79.3.1635-1644.2005","article-title":"Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus","volume":"79","author":"van den Brink","year":"2005","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106924_b0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"Ter Meulen","year":"2006","journal-title":"PLoS Med."},{"issue":"29","key":"10.1016\/j.intimp.2020.106924_b0495","doi-asserted-by":"crossref","first-page":"12123","DOI":"10.1073\/pnas.0701000104","article-title":"Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies","volume":"104","author":"Zhu","year":"2007","journal-title":"PNAS"},{"issue":"5","key":"10.1016\/j.intimp.2020.106924_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected receptor functional mimicry elucidates activation of coronavirus fusion","volume":"176","author":"Walls","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0505","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbrc.2005.05.089","article-title":"A human SARS-CoV neutralizing antibody against epitope on S2 protein","volume":"333","author":"Duan","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0510","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/427242","article-title":"Development and characterization of a severe acute respiratory syndrome\u2014associated coronavirus\u2014neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice","volume":"191","author":"Greenough","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0515","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jmb.2009.03.042","article-title":"Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain","volume":"388","author":"Pak","year":"2009","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0520","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jviromet.2004.04.009","article-title":"Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus","volume":"120","author":"Berry","year":"2004","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.intimp.2020.106924_b0525","article-title":"Potential neutralizing antibodies discovered for novel corona virus using machine learning","author":"Magar","year":"2020","journal-title":"arXiv"},{"issue":"19","key":"10.1016\/j.intimp.2020.106924_b0530","doi-asserted-by":"crossref","first-page":"20471","DOI":"10.1074\/jbc.M400798200","article-title":"Identification of SNAREs involved in synaptotagmin VII-regulated lysosomal exocytosis","volume":"279","author":"Rao","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.intimp.2020.106924_b0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000197","article-title":"Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway","volume":"4","author":"Sui","year":"2008","journal-title":"PLoS Pathog."},{"issue":"9","key":"10.1016\/j.intimp.2020.106924_b0540","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nbt1135","article-title":"Human antibodies from transgenic animals","volume":"23","author":"Lonberg","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2020.106924_b0545","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal 1 antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"issue":"6496","key":"10.1016\/j.intimp.2020.106924_b0550","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2020.106924_b0555","unstructured":"Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19. Available from: https:\/\/www.biospace.com\/article\/releases\/roivant-announces-development-of-anti-gm-csf-monoclonal-antibody-to-prevent-and-treat-acute-respiratory-distress-syndrome-ards-in-patients-with-covid-19\/."},{"key":"10.1016\/j.intimp.2020.106924_b0560","unstructured":"I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19). Available from: http:\/\/ir.i-mabbiopharma.com\/news-releases\/news-release-details\/i-mab-biopharma-announces-development-tjm2-treat-cytokine?from=timeline&isappinstalled=0."},{"key":"10.1016\/j.intimp.2020.106924_b0565","unstructured":"Humanigen Partners With CTI, A Leading Contract Research Organization, For Planned Phase III Study For Lenzilumab For Coronavirus Treatment. 30 March 2020]; Available from: https:\/\/www.humanigen.com\/press\/Humanigen-Partners-With-CTI%2C-A-Leading-Contract-Research-Organization%2C-For-Planned-Phase-III-Study-For-Lenzilumab-For-Coronavirus-Treatment."},{"key":"10.1016\/j.intimp.2020.106924_b0570","unstructured":"COVID-19 Novartis response."},{"key":"10.1016\/j.intimp.2020.106924_b0575","unstructured":"Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19. [25 March 2020]; Available from: https:\/\/investors.vir.bio\/news-releases\/news-release-details\/vir-biotechnology-proceeding-two-clinical-development-candidates."},{"key":"10.1016\/j.intimp.2020.106924_b0580","unstructured":"Distributed Bio optimizes anti-SARS protective antibodies to block the novel coronavirus. [31 March 2020]; Available from: https:\/\/www.distributedbio.com\/covid19."},{"key":"10.1016\/j.intimp.2020.106924_b0585","unstructured":"AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19. [12 March 2020]; Available from: https:\/\/www.abcellera.com\/news\/2020-03-abcellera-and-lilly-codevelopment."},{"key":"10.1016\/j.intimp.2020.106924_b0590","unstructured":"Tiziana Life Sciences plc To Expedite Development of its Fully Human Anti-Interleukin-6-Receptor Monoclonal Antibody, a Potential Treatment of Certain Patients Infected with Coronavirus COVID-19. [11 March 2020]; Available from: https:\/\/www.tizianalifesciences.com\/news-item?s=2020-03-11-tiziana-life-sciences-plc-to-expedite-development-of-its-fully-human-anti-interleukin-6-receptor-monoclonal-antibody-a-potential-treatment-of-certain-patients-infected-with-coronavirus-covid-19."},{"key":"10.1016\/j.intimp.2020.106924_b0595","unstructured":"Aqualung Therapeutics Advances Its Investigational Monoclonal Antibody into IND-Enabling Studies of Acute Respiratory Distress Syndrome (ARDS) And Ventilator-Induced Lung Injury (VILI). [18 March 2020]; Available from: https:\/\/www.accesswire.com\/581410\/Aqualung-Therapeutics-Advances-Its-Investigational-Monoclonal-Antibody-into-IND-Enabling-Studies-of-Acute-Respiratory-Distress-Syndrome-ARDS-And-Ventilator-Induced-Lung-Injury-VILI."},{"key":"10.1016\/j.intimp.2020.106924_b0600","unstructured":"Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19. [6 March 2020]; Available from: http:\/\/www.harbourbiomed.com\/en\/newsContent.html#135."},{"key":"10.1016\/j.intimp.2020.106924_b0605","unstructured":"Nascent biotech investigation drug product, pritumumab, to be studied as a potential therapeutic agent against (coronavirus) COVID-19. [3 March 2020]; Available from: https:\/\/apnews.com\/6ff39d8992ddd98d4422acc9b5e4b9c2."},{"key":"10.1016\/j.intimp.2020.106924_b0610","unstructured":"Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients. [30 March 2020]; Available from: https:\/\/www.cytodyn.com\/newsroom\/press-releases\/detail\/401\/three-additional-patients-with-severe-covid-19-treated-with."},{"key":"10.1016\/j.intimp.2020.106924_b0615","unstructured":"InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx\u2019s anti-C5a Technology. [31 March 2020]; Available from: https:\/\/www.inflarx.de\/Home\/Investors\/Press-Releases\/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html."},{"key":"10.1016\/j.intimp.2020.106924_b0620","unstructured":"Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19. Available from: https:\/\/investors.adaptivebiotech.com\/news-releases\/news-release-details\/amgen-and-adaptive-biotechnologies-announce-strategic."},{"key":"10.1016\/j.intimp.2020.106924_b0625","unstructured":"Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature [May 18, 2020]; Available from: https:\/\/investors.vir.bio\/node\/6981\/pdf."},{"key":"10.1016\/j.intimp.2020.106924_b0630","unstructured":"SAB Biotherapeutics: rapidly responding to COVID-19. Available from: https:\/\/sabbiotherapeutics.com\/covid-19\/."},{"key":"10.1016\/j.intimp.2020.106924_b0635","unstructured":"ImmunoPrecise Provides Updates on B Cell Select\u2122 and Deep Display\u2122 Programs for SARS-CoV-2 Antibody Discovery. [April 17,2020]; Available from: https:\/\/www.immunoprecise.com\/immunoprecise-provides-updates-on-b-cell-select-and-deep-display-programs-for-sars-cov-2-antibody-discovery\/."},{"key":"10.1016\/j.intimp.2020.106924_b0640","unstructured":"Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease. [11 March 2020]; Available from: https:\/\/investors.emergentbiosolutions.com\/node\/19256\/pdf."},{"key":"10.1016\/j.intimp.2020.106924_b0645","unstructured":"GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19. [30 March 2020]; Available from: https:\/\/www.globenewswire.com\/news-release\/2020\/03\/30\/2008438\/0\/en\/GigaGen-Initiates-Development-of-Recombinant-Polyclonal-Antibody-Therapy-for-COVID-19.html."},{"key":"10.1016\/j.intimp.2020.106924_b0650","unstructured":"NuGenerex. Ii-Key-nCOV Peptide Vaccine.Overview. [19 March 2020]; Available from: https:\/\/storage.googleapis.com\/wzukusers\/user-26831283\/documents\/5e73891471930g8BqVxh\/Ii-Key-nCOV%20Peptide%20Vaccine.Overview.3%2019%2020.pdf."},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0655","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1172\/JCI89857","article-title":"Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects","volume":"127","author":"Bekerman","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2020.106924_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China","author":"Zhang","year":"2020","journal-title":"Clin. Immunol."},{"issue":"10230","key":"10.1016\/j.intimp.2020.106924_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30691-7","article-title":"Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","volume":"395","author":"Ritchie","year":"2020","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2020.106924_b0670","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.str.2015.12.015","article-title":"Family-wide structural analysis of human numb-associated protein kinases","volume":"24","author":"Sorrell","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.intimp.2020.106924_b0675","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2018.05.001","article-title":"Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment","volume":"155","author":"Pu","year":"2018","journal-title":"Antiviral Res."},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0680","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis"},{"key":"10.1016\/j.intimp.2020.106924_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105967","article-title":"Baricitinib-a januase kinase inhibitor-not an ideal option for management of covid 19","author":"Praveen","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2020.106924_b0690","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30262-0","article-title":"Baricitinib for COVID-19: a suitable treatment?","author":"Favalli","year":"2020","journal-title":"Lancet Infect. Dis"},{"key":"10.1016\/j.intimp.2020.106924_b0695","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12967-020-02430-9","article-title":"Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)","volume":"18","author":"Kim","year":"2020","journal-title":"J. Translational Med."},{"issue":"2","key":"10.1016\/j.intimp.2020.106924_b0700","doi-asserted-by":"crossref","DOI":"10.3747\/co.26.4345","article-title":"Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma","volume":"26","author":"Owen","year":"2019","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.intimp.2020.106924_b0705","article-title":"COVID-19: A drug repurposing and biomarker identification by using comprehensive gene-disease associations through protein-protein interaction network analysis","author":"Kumar","year":"2020","journal-title":"Preprints"},{"key":"10.1016\/j.intimp.2020.106924_b0710","doi-asserted-by":"crossref","unstructured":"Y.F. Zheng, S.A. Liu, Prevent COVID-19 Severity by Repurposing mTOR Inhibitors. 2020.Preprints. doi:10.20944\/preprints202004.0060.v1.","DOI":"10.20944\/preprints202004.0060.v1"},{"issue":"2","key":"10.1016\/j.intimp.2020.106924_b0715","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CCM.0b013e3182a2727d","article-title":"Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure","volume":"42","author":"Wang","year":"2014","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.intimp.2020.106924_b0720","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for human coronavirus","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov."},{"issue":"24","key":"10.1016\/j.intimp.2020.106924_b0725","doi-asserted-by":"crossref","first-page":"15189","DOI":"10.1128\/JVI.79.24.15189-15198.2005","article-title":"The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity","volume":"79","author":"Barretto","year":"2005","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0730","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/095632020901900402","article-title":"Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme","volume":"19","author":"Chen","year":"2009","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.intimp.2020.106924_b0735","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3332\/ecancer.2020.1022","article-title":"Associations between immune-suppressive and stimulating drugs and novel COVID-19\u2014a systematic review of current evidence","volume":"14","author":"Russell","year":"2020","journal-title":"ecancermedicalscience"},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0740","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/ajt.13085","article-title":"MERS CoV infection in two renal transplant recipients: case report","volume":"15","author":"AlGhamdi","year":"2015","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0745","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.virusres.2012.02.002","article-title":"Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506","volume":"165","author":"Carbajo-Lozoya","year":"2012","journal-title":"Virus Res."},{"issue":"6","key":"10.1016\/j.intimp.2020.106924_b0750","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1021\/acsmedchemlett.0c00190","article-title":"A role for metal-based drugs in fighting Covid-19 infection? the case of auranofin","volume":"11","author":"Marzo","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0755","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12977-015-0178-0","article-title":"Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV\/AIDS","volume":"12","author":"Savarino","year":"2015","journal-title":"Retrovirology"},{"issue":"4","key":"10.1016\/j.intimp.2020.106924_b0760","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2567.2007.02679.x","article-title":"Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3","volume":"122","author":"Kim","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2020.106924_b0765","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.virol.2020.05.002","article-title":"The FDA-approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells","volume":"547","author":"Rothan","year":"2020","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0770","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1185\/030079903125002757","article-title":"TNF-[alpha] inhibition for potential therapeutic modulation of SARS coronavirus infection","volume":"20","author":"Tobinick","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.intimp.2020.106924_b0775","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s10753-014-9943-9","article-title":"Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice","volume":"37","author":"Zhu","year":"2014","journal-title":"Inflammation"},{"issue":"5922","key":"10.1016\/j.intimp.2020.106924_b0780","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1126\/science.1168988","article-title":"CD24 and Siglec-10 selectively repress tissue damage\u2013induced immune responses","volume":"323","author":"Chen","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.intimp.2020.106924_b0785","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2018.07.004","article-title":"CD24 and Fc fusion protein protects SIVmac239-infected Chinese rhesus macaque against progression to AIDS","volume":"157","author":"Tian","year":"2018","journal-title":"Antiviral Res."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2020.106924_b0790","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000362724","article-title":"One hormone, two actions: anti-and pro-inflammatory effects of glucocorticoids","volume":"22","author":"Cruz-Topete","year":"2015","journal-title":"NeuroImmunoModulation"},{"issue":"1","key":"10.1016\/j.intimp.2020.106924_b0795","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jinf.2020.03.062","article-title":"The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis","volume":"81","author":"Yang","year":"2020","journal-title":"J. Infect."},{"issue":"10223","key":"10.1016\/j.intimp.2020.106924_b0800","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.intimp.2020.106924_b0805","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1378\/chest.129.6.1441","article-title":"Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience","volume":"129","author":"Chen","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.intimp.2020.106924_b0810","unstructured":"W. Alhazzani, et al., Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19), Intensive Care Med., 2020, 1\u201334."},{"issue":"3","key":"10.1016\/j.intimp.2020.106924_b0815","first-page":"179","article-title":"Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy","volume":"43","author":"Xiao","year":"2004","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.intimp.2020.106924_b0820","first-page":"1348","article-title":"Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence","volume":"84","author":"Li","year":"2004","journal-title":"Zhonghua Yi Xue Za Zhi."},{"issue":"6","key":"10.1016\/j.intimp.2020.106924_b0825","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of theCytokine Storm'in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J. Infect."},{"issue":"9","key":"10.1016\/j.intimp.2020.106924_b0830","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/CM9.0000000000000791","article-title":"Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial","volume":"133","author":"Qin","year":"2020","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.intimp.2020.106924_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.039","article-title":"Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1","author":"Fang","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.intimp.2020.106924_b0840","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/d41586-020-01824-5","article-title":"Coronavirus breakthrough: dexamethasone is first drug shown to save lives","volume":"582","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.106924_b0845","unstructured":"WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients. [cited 2020 29 Jun]; Available from: https:\/\/www.who.int\/news-room\/detail\/16-06-2020-who-welcomes-preliminary-results-about-dexamethasone-use-in-treating-critically-ill-covid-19-patients."},{"key":"10.1016\/j.intimp.2020.106924_b0850","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. [cited 2020 29 Jun]; Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"10.1016\/j.intimp.2020.106924_b0855","article-title":"Effect of Dexamethasone in Hospitalized Patients with COVID-19","author":"Horby","year":"2020","journal-title":"Preliminary Report. medRxiv"},{"key":"10.1016\/j.intimp.2020.106924_b0860","doi-asserted-by":"crossref","unstructured":"S.U. Khan, T.T. Htar, Deciphering the binding mechanism of Dexamethasone against SARS-CoV-2 Main Protease: Computational molecular modelling approach. ChemRxiv. 2020. Preprint. doi:10.26434\/chemrxiv.12517535.v1.","DOI":"10.26434\/chemrxiv.12517535.v1"},{"key":"10.1016\/j.intimp.2020.106924_b0865","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia","volume":"395","author":"Shang","year":"2020","journal-title":"Lancet"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920324309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920324309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:46:38Z","timestamp":1762551998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920324309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":173,"alternative-id":["S1567576920324309"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106924","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapeutic approaches to curtail COVID-19","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106924"}}